Glucolipotoxicity, β-Cells, and Diabetes: The Emperor Has No Clothes
2019/09/14 by Gordon C. Weir · 28 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Pancreatic function and diabetes #Metabolism, Diabetes, and Cancer #Diabetes Management and Research
paper · pdf · doi:10.2337/db19-0138
Abstract
Reduction of β-cell mass and function is central to the pathogenesis of type 2 diabetes. The terms glucotoxicity, lipotoxicity, and glucolipotoxicity are used to describe potentially responsible processes. The premise is that chronically elevated glucose levels are toxic to β-cells, that elevated lipid levels in the form of circulating free fatty acids (FFA) also have toxic effects, and that the combination of the two, glucolipotoxicity, is particularly harmful. Much work has shown that high concentrations of FFA can be very damaging to β-cells when used for in vitro experiments, and when infused in large amounts in humans and rodents they produce suppression of insulin secretion. The purpose of this Perspective is to raise doubts about whether the FFA levels found in real-life situations are ever high enough to cause problems. Evidence supporting the importance of glucotoxicity is strong because there is such a tight correlation between defective insulin secretion and rising glucose levels. However, there is virtually no convincing evidence that the alterations in FFA levels occurring during progression to diabetes are pathogenic. Thus, the terms lipotoxicity and glucolipotoxicity should be used with great caution, if at all, because evidence supporting their importance has not yet emerged.
Cited by
- Evolution of the diagnostic value of “the sugar of the blood”: hitting the sweet spot to identify alterations in glucose dynamics
- Glycerolipid Cycling in Thermogenesis, Energy Homeostasis, Signaling, and Diseases
- Effects of Hypertriglyceridemia With or Without NEFA Elevation on β-cell Function and Insulin Clearance and Sensitivity
- Recent Insights Into Mechanisms of β-Cell Lipo- and Glucolipotoxicity in Type 2 Diabetes. [europepmc]
- Inadequate β-cell mass is essential for the pathogenesis of type 2 diabetes. [europepmc]
- Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma. [europepmc]
- Obesity Is Associated With Increased Basal and Postprandial β-Cell Insulin Secretion Even in the Absence of Insulin Resistance. [europepmc]
- Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks. [europepmc]
- The Multifunctionality of CD36 in Diabetes Mellitus and Its Complications-Update in Pathogenesis, Treatment and Monitoring. [europepmc]
- Combined transcriptome and proteome profiling of the pancreatic β-cell response to palmitate unveils key pathways of β-cell lipotoxicity. [europepmc]
- Association between triglyceride-glucose index and risk of incident diabetes: a secondary analysis based on a Chinese cohort study : TyG index and incident diabetes. [europepmc]
- Nrf2: The Master and Captain of Beta Cell Fate. [europepmc]
- Beta-Cell Mass in Obesity and Type 2 Diabetes, and Its Relation to Pancreas Fat: A Mini-Review. [europepmc]
- Normal and defective pathways in biogenesis and maintenance of the insulin storage pool. [europepmc]
- Mechanisms of Beta-Cell Apoptosis in Type 2 Diabetes-Prone Situations and Potential Protection by GLP-1-Based Therapies. [europepmc]
- The β-cell glucose toxicity hypothesis: Attractive but difficult to prove. [europepmc]
- β-Cell Death in Diabetes: Past Discoveries, Present Understanding, and Potential Future Advances. [europepmc]
- Why does obesity cause diabetes? [europepmc]
- SGLT2 inhibitors therapy protects glucotoxicity-induced β-cell failure in a mouse model of human KATP-induced diabetes through mitigation of oxidative and ER stress. [europepmc]
- Recent Advances in Understanding Nrf2 Agonism and Its Potential Clinical Application to Metabolic and Inflammatory Diseases. [europepmc]
- XBP1 maintains beta cell identity, represses beta-to-alpha cell transdifferentiation and protects against diabetic beta cell failure during metabolic stress in mice. [europepmc]
- Exercise training modulates adipokine dysregulations in metabolic syndrome. [europepmc]
- Research progress on the mechanism of beta-cell apoptosis in type 2 diabetes mellitus. [europepmc]
- Sphingolipid subtypes differentially control proinsulin processing and systemic glucose homeostasis. [europepmc]
- Palmitoylation couples insulin hypersecretion with β cell failure in diabetes. [europepmc]
- Mitochondrial Dysfunction, Oxidative Stress, and Inter-Organ Miscommunications in T2D Progression. [europepmc]
- Mitochondrial bioenergetics, metabolism, and beyond in pancreatic β-cells and diabetes. [europepmc]
- Interplay Between Insulin Resistance and Immune Dysregulation in Type 2 Diabetes Mellitus: Implications for Therapeutic Interventions. [europepmc]
Related